Brief: Nymox Pharmaceutical reports results of prostate cancer study
22/06/2016 14:30
June 22 (Reuters) - Nymox Pharmaceutical Corp NYMX.O
* Nymox reports long-term prostate cancer results in 7 year
prospective study of 995 u.s. Middle-Aged and elderly men
without cancer
* Men who received fexapotide showed a major reduction in
incidence of prostate cancer, compared to placebo
* Men who received fexapotide showed major reduction in
incidence of prostate cancer versus placebo and versus known and
expected normal incidence of disease
* New data analysis has now shown statistically significant
and very low incidence of 1.3% for prostate cancer in comparable
fexapotide treated bph population
Source text for Eikon: ID:nGNXMWKTWa
Further company coverage: NYMX.O
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba